RESUMEN
Pulmonary hypertension (PH) is a frequently under recognized complication of myelofibrosis (MF). The pathophysiology of PH in MF is unknown and no definitive therapies have been established. We studied 15 patients with MF-associated PH and compared their echocardiographic and PH relevant biomarkers (nitric oxide (NO), N-terminal pro-hormone of brain natriuretic peptide (NT-pro BNP), von Willebrand antigen (vWB), ristocetin-cofactor activity (RCA) and uric acid (UA)) pre- and post-ruxolitinib treatment. Ruxolitinib decreased the plasma levels of NT-pro BNP (73%; P=0.043), UA (60%), vWB (86%) and RCA (73%; P=0.036). Improvements in echocardiographic findings were also seen in 66% of patients (P=0.022). Furthermore, marked increase in NO compared with baseline (69.75 vs 40.1 picomolar (pM); P=0.001) was observed post-ruxolitinib therapy, whereas no changes were noted with conventional therapies. Treatment with ruxolitinib also resulted in the reduction of key cytokines (tumor necrosis factor alpha, interleukin-4 (IL-4), IL-6 and IL-8) and induction of interferon-gamma. Animal studies further supported the role of ruxolitinib in the induction of NO levels. In conclusion, aberrant Janus kinase (JAK)-signal transducer and activator of transcription signaling in MF may mediate PH through dysregulation of NO and cytokine levels, which can be restored by therapy with JAK inhibitors suggesting that inhibition of this pathway is a novel target for the management of patients with PH.
Asunto(s)
Hipertensión Pulmonar/tratamiento farmacológico , Hipertensión Pulmonar/etiología , Mielofibrosis Primaria/complicaciones , Pirazoles/uso terapéutico , Anciano , Anciano de 80 o más Años , Animales , Biomarcadores/sangre , Citocinas/sangre , Modelos Animales de Enfermedad , Ecocardiografía , Femenino , Ferritinas/sangre , Humanos , Hipertensión Pulmonar/diagnóstico , Quinasas Janus/antagonistas & inhibidores , Masculino , Ratones Noqueados , Persona de Mediana Edad , Óxido Nítrico/sangre , Nitrilos , Mielofibrosis Primaria/sangre , Mielofibrosis Primaria/genética , PirimidinasRESUMEN
Circulating cardiac troponins are markers of myocardial injury. We sought to determine whether cardiac troponin I (cTnI), measured by a sensitive assay, is associated with disease severity and prognosis in pulmonary arterial hypertension (PAH). cTnI was measured in 68 patients with PAH diagnostic category 1 in a research-based sensitive immunoanalyser with a lower limit of detection of 0.008 ng · mL(-1). The associations between cTnI and PAH severity and clinical outcomes were assessed using Chi-squared and Wilcoxon rank sum tests, Kaplan-Meier analysis and Cox regression models. cTnI was detected in 25% of patients. Patients with detectable cTnI had more advanced functional class symptoms, a shorter 6-min walk distance, more pericardial effusions, larger right atrial area, and higher B-type natriuretic peptide and C-reactive protein levels. 36-month transplant-free survival was 44% in patients with detectable cTnI versus 85% in those with undetectable cTnI. cTnI was associated with a 4.7-fold increased risk of death related to right ventricular failure or transplant (hazard ratio 4.74, 95% CI 1.89-11.89; p<0.001), even when adjusted individually for known parameters of PAH severity. Elevated plasma cTnI, even at subclinically detectable levels, is associated with more severe disease and worse outcomes in patients with PAH.
Asunto(s)
Hipertensión Pulmonar , Índice de Severidad de la Enfermedad , Troponina I/sangre , Adulto , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Hipertensión Pulmonar Primaria Familiar , Femenino , Humanos , Hipertensión Pulmonar/sangre , Hipertensión Pulmonar/diagnóstico , Hipertensión Pulmonar/mortalidad , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Péptido Natriurético Encefálico/sangre , Derrame Pericárdico/sangre , Derrame Pericárdico/diagnóstico , Derrame Pericárdico/mortalidad , Valor Predictivo de las Pruebas , Pronóstico , Modelos de Riesgos Proporcionales , Factores de Riesgo , Sensibilidad y EspecificidadRESUMEN
Biomarkers are objectively measured characteristics used as indicators of disease in clinical practice and as surrogate endpoints in clinical trials. The six-minute walk test has been widely used as a trial endpoint in pulmonary arterial hypertension (PAH) to gain approval for targeted therapies. Other biomarkers have been studied to overcome certain limitations of the walk test. Potential clinical applications for biomarkers in PAH include screening, determination of prognosis, and monitoring response to therapy. Measurement of the B-type natriuretic peptides is currently recommended by guidelines, despite a lack of appropriate validation in the PAH population. Novel biomarkers based on recently discovered pathobiologic pathways have been identified, like CXC chemokine ligand 10, C-reactive protein, high-density lipoprotein cholesterol and growth-differentiation factor-15. Rigorous statistical, biologic and clinical validation should be necessary before any biomarker can be endorsed for widespread clinical use.